Company Name Versartis
Mailing Address 275 Shoreline Drive Mountain View, CA 94065
Company Description Versartis is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis has licensed the rights to three products (VRS-826, VRS-859, and VRS-317) from Amunix.
Proceeds Purposes The proceeds from this financing will primarily be used to prepare for an international Phase 3 pediatric trial of VRS-317, the company’s proprietary long-acting recombinant human growth hormone (rhGH) for the treatment of growth hormone deficiency (GHD).